Daratumumab improves the hematological response and kidney function of patients with light chain deposition disease.

Chin Med J (Engl) · 2025 · PMC11745854 · PMID 39602317

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significanceP = 0.057so close (0.05 < p ≤ 0.1)

In comparison, only one patient in the daratumumab group developed ESKD; however, the difference did not reach statistical significance ( P = 0.057).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.